Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Sonki's Links List -- Ignore unavailable to you. Want to Upgrade?

To: ANANT who wrote (90)	4/20/1998 8:07:00 PM
From: Sonki	Read Replies (1) \| Respond to of 395

LLY conf call summary Message 4134421 ANYONE READING THESE FEEL FREE TO ADD U R LINKS HERE..I USE IT FOR HISTORICAL REF. .. hope u sold athm erly morn. link to internet index. ATHM down 3.xx fnews.yahoo.com Drug maker Eli Lilly & Co. (NYSE:LLY - news) gained $3 9/16 to $71 15/16 this morning after reporting first quarter earnings of $0.47 per share (before charges) compared with $0.38 for the year-earlier period and a penny higher than the First Call mean estimate. The company's worldwide sales for the quarter increased 16% to $2.269 billion, with Prozac and Zyprexa leading the sales growth. Also, preliminary reports (not yet released) indicate that Lilly's drug Evista is effective at preventing breast cancer without increasing the risk of uterine cancer. Pfizer (NYSE:PFE - news) also jumped $6 7/8 to $112 1/16 after The Wall Street Journal reported that the pharmaceutical company's new impotence drug Viagra is "already one of the fastest-selling drugs in the history of medicine" after a mere two weeks on the market. Also, PaineWebber upgraded Pfizer to "attractive" from "neutral." cd:fyi Cendant named a new chief financial officer, Michael Wargotz, for its troubled Alliance Marketing division.